Skip to content

Yoga breathing for cancer chemotherapy-associated symptoms and quality of life: results of a pilot randomized controlled trial.

Anand Dhruva, Christine Miaskowski, Donald Abrams, Michael Acree, Bruce Cooper, Steffanie Goodman, Frederick M Hecht

The Journal of Alternative and Complementary Medicine April 23, 2012 DOI: 10.1089/acm.2011.0555 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial (pilot) Pilot study Peer reviewed
Sample size 16
Population Patients receiving cancer chemotherapy at a university medical center
Duration Pranayama during two consecutive cycles of chemotherapy; weekly classes with home practice
Topics Anxiety Depression Meditation
Keywords Humans Neoplasms Fatigue Antineoplastic agents Breathing exercises Yoga Pilot projects Stress, psychological Respiration Quality of life Adult Middle aged Female Sleep wake disorders
Key findings Greater pranayama practice dose was associated with improved symptom and quality-of-life scores, with sleep disturbance, anxiety, and mental quality of life reaching or approaching significance. The authors conclude pranayama may improve these outcomes and was feasible, but call for a larger study to confirm the findings.

Abstract

Background: Many debilitating symptoms arise from cancer and its treatment that are often unrelieved by established methods. Pranayama, a series of yogic breathing techniques, may improve cancer-related symptoms and quality of life, but it has not been studied for this purpose.

Objectives: A pilot study was performed to evaluate feasibility and to test the effects of pranayama on cancer-associated symptoms and quality of life.

Design: This was a randomized controlled clinical trial comparing pranayama to usual care.

Setting: The study was conducted at a university medical center. Subjects: Patients receiving cancer chemotherapy were randomized to receive pranayama immediately or after a waiting period (control group).

Interventions: The pranayama intervention consisted of four breathing techniques taught in weekly classes and practiced at home. The treatment group received pranayama during two consecutive cycles of chemotherapy. The control group received usual care during their first cycle, and received pranayama during their second cycle of chemotherapy. Outcome measures: Feasibility, cancer-associated symptoms (fatigue, sleep disturbance, anxiety, depression, stress), and quality of life were the outcomes.

Results: Class attendance was nearly 100% in both groups. Sixteen (16) participants were included in the final intent-to-treat analyses. The repeated-measures analyses demonstrated that any increase in pranayama dose, with dose measured in the number of hours practiced in class or at home, resulted in improved symptom and quality-of-life scores. Several of these associations--sleep disturbance (p=0.04), anxiety (p=0.04), and mental quality of life (p=0.05)--reached or approached statistical significance.

Conclusions: Yoga breathing was a feasible intervention among patients with cancer receiving chemotherapy. Pranayama may improve sleep disturbance, anxiety, and mental quality of life. A dose-response relationship was found between pranayama use and improvements in chemotherapy-associated symptoms and quality of life. These findings need to be confirmed in a larger study.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Explore topics